Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026 (NASDAQ:RIGL)

Group 1 - The article focuses on trading biotech stocks around significant events such as trial results and NDA/BLA approvals, indicating a strategic approach to investment in this sector [1] - The analysis covers companies in industries regulated by the FDA, highlighting the importance of regulatory factors in investment decisions [1] Group 2 - The author discloses no current stock or derivative positions in the companies mentioned, ensuring an unbiased perspective in the analysis [2] - The article emphasizes that past performance does not guarantee future results, which is a critical consideration for investors [3]